Concepedia

L. Bonanno

LB

Statistics

Publications

3

Citations

123

H-Index

3

Active since

2022

Affiliations

AstraZeneca (United States)(Current)

Istituto Oncologico Veneto

Yonsei University

Massachusetts General Hospital

Seoul National University Bundang Hospital

L. Bonanno is an author at AstraZeneca (United States) specializing in oncology, biomarker validation, and molecular biomarker validation.

Publications per year

2022–2025

3

Publications

3

EP08.02-140 MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC Post-Osimertinib

M-j. Ahn, F. De Marinis, L. Bonanno et al. · Journal of Thoracic Oncology · 2022 · 71 citations

, , +9

Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study

Filippo de Marinis, Tae Min Kim, L. Bonanno et al. · Annals of Oncology · 2025 · 33 citations · Full text

, , +16

1O: Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD

X. Le, L. Hendriks, Alessandro Morabito et al. · Journal of Thoracic Oncology · 2025 · 19 citations · Full text

, , +6

1–3 of 3